Regeneron Pharmaceuticals, Inc.

( )
REGN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.37%333.610.0%$4529.69m
NVAXNovavax, Inc. -3.43%160.5579.4%$722.22m
BNTXBioNTech SE 0.67%262.850.0%$709.55m
AMGNAmgen, Inc. 1.80%206.781.4%$547.92m
SNSSSunesis Pharmaceuticals, Inc. -1.92%6.140.7%$429.21m
REGNRegeneron Pharmaceuticals, Inc. 1.59%552.112.7%$426.22m
GILDGilead Sciences, Inc. 1.52%66.901.0%$414.02m
CCXIChemoCentryx, Inc. 3.76%33.652.9%$399.69m
ILMNIllumina, Inc. 0.87%414.083.3%$377.90m
XLRNAcceleron Pharma, Inc. 0.43%173.745.3%$364.00m
VRTXVertex Pharmaceuticals, Inc. 2.55%185.411.9%$264.85m
BIIBBiogen, Inc. -0.59%268.131.7%$232.27m
OCGNOcugen, Inc. 0.85%8.330.0%$180.05m
XENEXenon Pharmaceuticals, Inc. -2.96%29.810.4%$166.66m
DNAGinkgo Bioworks Holdings, Inc. 20.21%14.810.0%$162.54m

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.